在帕金森病模型中,孟曼丁调节神经炎症和运动协调
Hyunha Choi1, Subin Hwang1, Hyeyeon Cho1
1Data Convergence Drug Research Center, Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon 34114, South Korea; College of Pharmacy, Chungnam National University, Daejeon, South Korea.
Brain research
|November 6, 2025
概括
孟曼丁在帕金森病 (PD) 模型中显示出潜力,通过减少神经炎症和改善运动功能. 然而,它没有影响关键的PD病理,如α-synuclein积累.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 孟曼丁是阿尔茨海默病的NMDA受体对手,可能会影响神经炎症.
- 它在帕金森病 (PD) 中的潜在治疗作用需要进行调查.
研究的目的:
- 在PD模型中评估美曼丁对神经炎症和运动缺陷的影响.
- 评估其对微质激活和α-synuclein病理学的影响.
主要方法:
- 试验室内:用LPS激活的BV-2微质细胞接受了记忆剂的治疗.
- 在体内:mThy1-αSyn转基因小鼠口服记忆素5个月.
- 进行了行为测试 (光束行走) 和免疫组织化学分析.
主要成果:
- 孟坦丁降低了微质细胞中TNF-α和IL-6的分泌,降低了TLR4和IκB信号的调节.
- 口服孟坦丁在小鼠中改善了运动功能,与微质激活减少相关.
- 酸化α-synuclein或氨酸氧酶水平没有显著变化.
结论:
- 孟曼丁通过调节炎症反应和改善PD模型中的运动缺陷来证明神经保护潜力.
- 它对核心PD神经病理,如α-synuclein聚合的疗效似乎有限.
- 需要进一步的研究来澄清孟坦因在PD治疗中的作用.
相关概念视频
Parkinson's Disease: Treatment
954
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
954
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Neural Regulation
43.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K
Alzheimer's Disease: Treatment
782
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
782
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
527
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
527


